Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 3, 2007, Pages 975-981

  Cigana, Cristina ^a   Assael, Baroukh Maurice ^a   Melotti, Paola ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; JOSAMYCIN; MACROLIDE; MESSENGER RNA; TRANSCRIPTION FACTOR SP1; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL LINE; CONTROLLED STUDY; CYSTIC FIBROSIS; DNA BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; HUMAN; HUMAN CELL; INHIBITION KINETICS; LUNG FUNCTION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY EPITHELIUM; TREATMENT RESPONSE;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CELL LINE; CELLS, CULTURED; CYSTIC FIBROSIS; DNA; EPITHELIAL CELLS; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; HUMANS; INTERLEUKIN-6; JOSAMYCIN; NF-KAPPA B; RESPIRATORY MUCOSA; RNA; SP1 TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33847688940     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01142-06     Document Type: Article

References (46)

1. Aldallal, N., E. E. McNaughton, L. J. Manzel, A. M. Richards, J. Zabner, T. W. Ferkol, and D. C. Look. 2002. Inflammatory response in airway epithelial cells isolated from patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 166:1248-1256.
2. Armstrong, D. S., K. Grimwood, J. B. Carlin, R. Carzino, J. P. Gutierrez, J. Hull, A. Olinsky, E. M. Phelan, C. F. Robertson, and P. D. Phelan. 1997. Lower airway inflammation in infants and young children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 156:1197-1204.
3. Asgrimsson, V., T. Gudjonsson, G. H. Gudmundsson, and O. Baldursson. 2006. Novel effects of azithromycin on tight junction proteins in human airway epithelia. Antimicrob. Agents Chemother. 50:1805-1812.
4. Baumann, U., M. King, E. M. App, S. Tai, A. Konig, J. J. Fischer, T. Zimmermann, W. Sextro, and H. von der Hardt. 2004. Long term azithromycin therapy in cystic fibrosis patients: a study on drug levels and sputum properties. Can. Respir. J. 11:151-155.
5. Becker, M. N., M. S. Sauer, M. S. Muhlebach, A. J. Hirsh, Q. Wu, M. W. Verghese, and S. H. Randell. 2004. Cytokine secretion by cystic fibrosis airway epithelial cells. Am. J. Respir. Crit. Care Med. 169:645-653.
6. Birke, F. W., C. J. Meade, and R. Anderskewitz. 2001. In vitro and in vivo pharmacological characterization of BIIL 284, a novel and potent leukotriene B (4) receptor antagonist. J. Pharmacol. Exp. Ther. 297:458-466.
7. Blease, K., A. Lewis, and H. K. Raymon. 2003. Emerging treatments for asthma. Expert Opin. Emerg. Drugs 8:71-81.
8. Bonfield, T. L., J. R. Panuska, M. W. Konstan, K. A. Hilliard, J. B. Hilliard, H. Ghnaim, and M. Berger. 1995. Inflammatory cytokines in cystic fibrosis lungs. Am. J. Respir. Crit. Care Med. 152:2111-2118.
9. Carrabino, S., D. Carpani, A. Livraghi, M. Di Cicco, D. Costantini, E. Copreni, C. Colombo, and M. Conese. 2006. Dysregulated interleukin-8 secretion and NF-kappaB activity in human cystic fibrosis nasal epithelial cells. J. Cyst. Fibros. 5:113-119.
10. Chmiel, J. F., and P. B. Davis. 2003. State of the art: why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection? Respir. Res. 4:8-29.
11. Cigana, C., E. Nicolis, M. Pasetto, B. M. Assael, and P. Melotti. 2005. Regulation of pro-inflammatory transcription factors by azithromycin in cystic fibrosis epithelial airway epithelial cells. Pediatr. Pulmonol. Suppl. 28:271.
12. Cigana, C., E. Nicolis, M. Pasetto, B. M. Assael, and P. Melotti. 2006. Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells. Biochem. Biophys. Res. Commun. 350:977-982.
13. Cozens, A. L., M. J. Yezzi, L. Chin, E. M. Simon, W. E. Finkbeiner, J. A. Wagner, and D. C. Gruenert. 1992. Characterization of immortal cystic fibrosis tracheobronchial gland epithelial cells. Proc. Natl. Acad. Sci. USA 89:5171-5175.
14. Culic, O., V. Erakovic, I. Cepelak, K. Barisic, K. Brajsa, Z. Ferencic, R. Galovic, I. Glojnaric, Z. Manojlovic, V. Munic, R. Novak-Mircetic, V. Pavicic-Beljak, M. Sucic, M. Veljaca, T. Zanic-Grubisic, and M. J. Parnham. 2002. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur. J. Pharmacol. 450:277-289.
15. Dakin, C. J., A. H. Numa, H. Wang, J. R. Morton, C. C. Vertzyas, and R. L. Henry. 2002. Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 165:904-910.
16. DiMango, E., A. J. Ratner, R. Bryan, S. Tabibi, and A. Prince. 1998. Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells. J. Clin. Investig. 101:2598-2606.
17. Di Paolo, A., C. Barbara, A. Chella, C. A. Angeletti, and M. Del Tacca. 2002. Pharmacokinetics of azithromycin in lung tissue, bronchial washing, and plasma in patients given multiple oral doses of 500 and 1000 mg daily. Pharmacol. Res. 46:545-550.
18. Ferrara, G., M. Losi, F. Franco, L. Corbetta, L. M. Fabbri, and L. Richeldi. 2005. Macrolides in the treatment of asthma and cystic fibrosis. Respir. Med. 99:1-10.
19. Hansen, C. R., T. Pressler, C. Koch, and N. Hoiby. 2005. Long-term azitromycin [sic] treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study. J. Cyst. Fibros. 4:35-40.
20. Ianaro, A., A. Ialenti, P. Maffia, L. Sautebin, L. Rombola, R. Carnuccio, T. Iuvone, F. D'Acquisto, and M. Di Rosa. 2000. Anti-inflammatory activity of macrolide antibiotics. J. Pharmacol. Exp. Ther. 292:156-163.
21. Ivetic Tkalcevic, V., B. Bosnjak, B. Hrvacic, M. Bosnar, N. Marjanovic, Z. Ferencic, K. Situm, O. Culic, M. J. Parnham, and V. Erakovic. 2006. Antiinflammatory activity of azithromycin attenuates the effects of lipopolysaccharide administration in mice. Eur. J. Pharmacol. 539:131-138.
22. Joseph, T., D. Look, and T. Ferkol. 2005. NF-kappaB activation and sustained IL-8 gene expression in primary cultures of cystic fibrosis airway epithelial cells stimulated with Pseudomonas aeruginosa. Am. J. Physiol. Lung Cell. Mol. Physiol. 288:L471-L479.
23. Kawamura-Sato, K., Y. Iinuma, T. Hasegawa, T. Horii, T. Yamashino, and M. Ohta. 2000. Effect of subinhibitory concentrations of macrolides on expression of flagellin in Pseudomonas aeruginosa and Proteus mirabilis. Antimicrob. Agents Chemother. 44:2869-2872.
24. Koehler, D. R., G. P. Downey, N. B. Sweezey, A. K. Tanswell, and J. Hu. 2004. Lung inflammation as a therapeutic target in cystic fibrosis. Am. J. Respir. Cell Mol. Biol. 31:377-381.
25. Konstan, M. W., and M. Berger. 1997. Current understanding of the inflammatory process in cystic fibrosis: onset and etiology. Pediatr. Pulmonol. 24:137-142.
26. Lee, K. W., Y. Lee, H. J. Kwon, and D. S. Kim. 2005. Sp1-associated activation of macrophage inflammatory protein-2 promoter by CpG-oligodeoxynucleotide and lipopolysaccharide. Cell. Mol. Life Sci. 62:188-198.
27. Liu, H., P. Sidiropoulos, G. Song, L. J. Pagliari, M. J. Birrer, B. Stein, J. Anrather, and R. M. Pope. 2000. TNF-alpha gene expression in macrophages: regulation by NF-kappa B is independent of c-Jun or C/EBP beta. J. Immunol. 164:4277-4285.
28. Muhlebach, M. S., and T. L. Noah. 2002. Endotoxin activity and inflammatory markers in the airways of young patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 165:911-915.
29. Nalca, Y., L. Jansch, F. Bredenbruch, R. Geffers, J. Buer, and S. Haussler. 2006. Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach. Antimicrob. Agents Chemother. 50:1680-1688.
30. Pirzada, O. M., J. McGaw, C. J. Taylor, and M. L. Everard. 2003. Improved lung function and body mass index associated with long-term use of macrolide antibiotics. J. Cyst. Fibros. 2:69-71.
31. Pradal, U., A. Delmarco, M. Morganti, M. Cipolli, E. Mini, and G. Cazzola. 2005. Long-term azithromycin in cystic fibrosis: another possible mechanism of action? J. Chemother. 17:393-400.
32. Rajan, S., G. Cacalano, R. Bryan, A. J. Ratner, C. U. Sontich, A. van Heerckeren, P. Davis, and A. Prince. 2000. Pseudomonas aeruginosa induction of apoptosis in respiratory epithelial cells: analysis of the effects of cystic fibrosis transmembrane conductance regulator dysfunction and bacterial virulence factors. Am. J. Respir. Cell Mol. Biol. 23:304-312.
33. Ribeiro, C. M., A. M. Paradiso, U. Schwab, J. Perez-Vilar, L. Jones, W. O'Neal, and R. C. Boucher. 2005. Chronic airway infection/inflammation induces a Ca2+i-dependent hyperinflammatory response in human cystic fibrosis airway epithelia. J. Biol. Chem. 280:17798-17806.
34. Rosenfeld, M., R. L. Gibson, S. McNamara, J. Emerson, J. L. Burns, R. Castile, P. Hiatt, K. McCoy, C. B. Wilson, A. Inglis, A. Smith, T. R. Martin, and B. W. Ramsey. 2001. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr. Pulmonol. 32:356-366.
35. Saiman, L., N. Mayer-Hamblett, P. Campbell, B. C. Marshall, and the Macrolide Study Group. 2005. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 172:1008-1012.
36. Shinkai, M., and B. K. Rubin. 2005. Macrolides and airway inflammation in children. Paediatr. Respir. Rev. 6:227-235.
37. Suzuki, J., R. Morishita, J. Amano, Y. Kaneda, and M. Isobe. 2000. Decoy against nuclear factor-kappa B attenuates myocardial cell infiltration and arterial neointimal formation in murine cardiac allografts. Gene Ther. 7:1847-1852.
38. Takizawa, H., M. Desaki, T. Ohtoshi, S. Kawasaki, T. Kohyama, M. Sato, M. Tanaka, T. Kasama, K. Kobayashi, J. Nakajima, and K. Ito. 1997. Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am. J. Respir. Crit. Care Med. 156:266-271.
39. Tateda, K., Y. Ishii, T. Matsumoto, T. Kobayashi, S. Miyazaki, and K. Yamaguchi. 2000. Potential of macrolide antibiotics to inhibit protein synthesis of Pseudomonas aeruginosa: suppression of virulence factors and stress response. J. Infect. Chemother. 6:1-7.
40. Tirouvanziam, R., S. de Bentzmann, C. Hubeau, J. Hinnrasky, J. Jacquot, B. Péault, and E. Puchelle. 2000. Inflammation and infection in naive human cystic fibrosis airway grafts. Am. J. Respir. Cell Mol. Biol. 23:121-127.
41. Tsai, W. C., M. L. Rodriguez, K. S. Young, J. C. Deng, V. J. Thannickal, K. Tateda, M. B. Hershenson, and T. J. Standiford. 2004. Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection. Am. J. Respir. Crit. Care Med. 170:1331-1339.
42. Tsytsykova, A. V., and A. E. Goldfeld. 2002. Inducer-specific enhanceosome formation controls tumor necrosis factor alpha gene expression in T lymphocytes. Mol. Cell. Biol. 22:2620-2631.
43. Venkatakrishnan, A., A. A. Stecenko, G. King, T. R. Blackwell, K. L. Brigham, J. W. Christman, and T. S. Blackwell. 2000. Exaggerated activation of nuclear factor-kappaB and altered IkappaB-beta processing in cystic fibrosis bronchial epithelial cells. Am. J. Respir. Cell Mol. Biol. 23:396-403.
44. Wagner, T., G. Soong, S. Sokol, L. Saiman, and A. Prince. 2005. Effects of azithromycin on clinical isolates of Pseudomonas aeruginosa from cystic fibrosis patients. Chest 128:912-919.
45. Wolter, J., S. Seeney, S. Bell, S. Bowler, P. Masel, and J. McCormack. 2002. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 57:212-216.
46. Zeitlin, P. L., L. Lu, J. Rhim, G. Cutting, G. Stetten, K. A. Kieffer, R. Craig, and W. B. Guggino. 1991. A cystic fibrosis bronchial epithelial cell line: immortalization by adeno-12-SV40 infection. Am. J. Respir. Cell Mol. Biol. 4:313-319.